Orchard Therapeutics PLC $ 6.99 0.14 (2.04%)
Volume:
503,223
Avg Vol (1m):
3,082,026
Market Cap $:
854.28 Mil
Enterprise Value $:
711.06 Mil
PE Ratio:
0.00
PB Ratio:
3.29
Financial Strength | 4/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 3.46 | ||
Equity-to-Asset | 0.69 | ||
Debt-to-Equity | 0.28 | ||
Debt-to-EBITDA | -0.34 | ||
Altman Z-Score | 1.79 | ||
WACC vs ROIC |
Profitability Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -5239.22 | ||
Net Margin % | -5134.01 | ||
ROE % | -61.22 | ||
ROA % | -45.96 | ||
ROC (Joel Greenblatt) % | -695.38 | ||
3-Year EBITDA Growth Rate | 1.2 | ||
3-Year EPS without NRI Growth Rate | 13.4 |
ORTX
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 3.29 | ||
PS Ratio | 219.06 | ||
EV-to-EBIT | -4.16 | ||
EV-to-EBITDA | -4.21 | ||
EV-to-Revenue | 222.89 | ||
Current Ratio | 5.74 | ||
Quick Ratio | 5.74 | ||
Days Sales Outstanding | 364.2 | ||
Days Payable | 2039.34 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -112.5 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 3.31 | ||
Earnings Yield (Greenblatt) % | -24.01 |